title: New therapeutics to treat castrate-resistant prostate cancer.
abstract: The effective treatment of castrate-resistant prostate cancer (CRPC) has proven to be very challenging. Until recently, docetaxel was the only therapeutic demonstrated to extend overall patient survival. Yet recently, a considerable number of new therapeutics have been approved to treat CRPC patients. These remarkable advances now give new tools for the therapeutic management of late-stage prostate cancer. In this review, we will examine mechanistic and clinical data of several newly approved therapeutics including the chemotherapeutic cabazitaxel, antiandrogen enzalutamide, endocrine disruptor abiraterone acetate, immunotherapy sipuleucel-T, and bone-targeting radiopharmaceutical alpharadin. In addition, we will examine other promising therapeutics that are currently in Phase III trials.
authors.affiliation: VKF American Hospital, Guzelbahce sokak, Nisantasi, Istanbul 34365, Turkey.
authors.forename: Omer
authors.initials: O
authors.lastname: Acar
authors.forename: Tarık
authors.initials: T
authors.lastname: Esen
authors.forename: Nathan A
authors.initials: NA
authors.lastname: Lack
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002369:Castration; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000628:therapy*; D011878:Radiotherapy / Q000379:methods*; D017211:Treatment Failure
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents